Given our observation that DS induces a TBK1-dependent but STING-independent activation of IFN-I, we hypothesized that combining DS with a STING agonist could enhance IFN-I signaling in tumor cells, potentially resulting in a synergistic anti-tumor effect. Here, TBK1 is linked to neoplasm.